Scott M. Coiante
2019
In 2019, Scott M. Coiante earned a total compensation of $1.8M as Chief Financial Officer at Aprea Therapeutics.
Compensation breakdown
| Bonus | $50,000 |
|---|---|
| Non-Equity Incentive Plan | $127,604 |
| Option Awards | $1,488,633 |
| Salary | $143,182 |
| Total | $1,809,419 |
Coiante received $1.5M in option awards, accounting for 82% of the total pay in 2019.
Coiante also received $50K in bonus, $127.6K in non-equity incentive plan and $143.2K in salary.
Rankings
In 2019, Scott M. Coiante's compensation ranked 6,423rd out of 13,971 executives tracked by ExecPay. In other words, Coiante earned more than 54.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,423 out of 13,971 | 54th |
Division Manufacturing | 2,427 out of 5,701 | 57th |
Major group Chemicals And Allied Products | 887 out of 2,200 | 60th |
Industry group Drugs | 752 out of 1,886 | 60th |
Industry Pharmaceutical Preparations | 553 out of 1,398 | 60th |
Source: SEC filing on April 29, 2020.
Coiante's colleagues
We found two more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2019.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020